Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

nd the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc.

Web site: http://www.pharmacyclics.com/http://www.yourcanceryourchoice.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to ... cancer patients. , Editorial and marketing groups within OncLive, which provides oncologists ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading ... the FirstSpirit Content Management System with new capabilities and enhancements designed to support ... companies will be well on their way to achieving digital transformation with less ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Zecurion, a ... Mac , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. ... in which more than 100 IT and information security professionals had participated. The beta ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... suffer a break up to eight times more likely to die, ... and women who break a hip are five to eight times ... fracture, a new study by Belgian researchers has found. , And, ... the first two years after the break, it never returns to ...
... , MONDAY, March 15 (HealthDay News) -- A ... sexual dysfunction in people with Parkinson,s disease has been ... main symptoms of Parkinson,s disease are movement problems, but ... noted lead guidelines author Dr. Theresa A. Zesiewicz, of ...
... boomer epidemic predicted , MONDAY, March 15 (HealthDay News) -- ... the 1990s, making it by far the most common form ... two new studies find. , More than 2 million Americans ... up from 1.6 million in 1992, according to one study. ...
... ... identify infants at high risk of developing childhood-onset obesity by measuring a newborn baby’s ... possible is called the Pea Pod® Infant Body Composition System. Located at Prentice Women’s ... , ...
... (TSE: 4503) today released the following statement in response to OSI Pharmaceuticals, (Nasdaq: OSIP ) rejection of Astellas, tender offer for $52.00 per share. , ... , ... ... ...
... are focused on the issue 24/7. , ... , , ... ... Rotary is committed to helping achieve the UN Millennium Development Goal that calls for a 50 percent reduction ...
Cached Medicine News:Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3Health News:Relief Sought for Secondary Parkinson's Symptoms 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 3Health News:Non-Melanoma Skin Cancers in the Millions and Rising 4Health News:Study to Identify Infants at High Risk for Developing Obesity 2Health News:Study to Identify Infants at High Risk for Developing Obesity 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 2Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 4Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 5Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 6Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 7Health News:Rotary Clubs Always Pumped for World Water Day 2Health News:Rotary Clubs Always Pumped for World Water Day 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: